" "
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ganymed’s IMAB027 Enters Phase I/II Clinical Trial for Ovarian Cancer

Published: Thursday, February 13, 2014
Last Updated: Thursday, February 13, 2014
Bookmark and Share
Second antibody from Ganymed’s ideal monoclonal antibody platform in the clinic.

Ganymed Pharmaceuticals AG has announced that the first patients are being enrolled and are starting treatment in a Phase I/II OVAR clinical trial to assess the safety, tolerability, and efficacy of IMAB027 as single agent for the treatment of advanced ovarian cancer.

IMAB027 is a highly specific monoclonal antibody targeting the tight junction protein Claudin-6 (CLDN6). The trial is being conducted in Germany, Belgium, Russia, and Ukraine.

“IMAB027 is the second antibody from Ganymed to enter clinical development that is based on our Ideal Monoclonal Antibody platform,” said Dr. Özlem Türeci, Chief Executive Officer and Chief Medical Officer of Ganymed.

Dr. Türeci continued, “Women with recurrent ovarian cancer have few therapeutic options. We believe that the unmatched cancer-cell selectivity of IMAB027 holds great promises of improving treatment options for these patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ganymed Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Conference will take place from January 13 to January 16, 2014 in San Francisco.
Thursday, December 26, 2013
Ganymed Pharmaceuticals Closes EUR 45 Million Financing Round
Company to accelerate clinical development of antibodies IMAB362 and IMAB027 for the treatment of cancer.
Monday, November 18, 2013
Ganymed’s IMAB362 Receives Orphan Drug Designation from FDA and EMA
IMAB362 receives orphan drug designation for the treatment of pancreatic cancer.
Monday, October 21, 2013
Scientific News
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
The Spice of Life
Scientists discover important genetic source of human diversity.
Removing Race from Human Genetic Research
A group of scientists are urging their colleagues to take a step forward and stop using racial categories when researching and studying human genetics.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Genetic Cause of Rare Allergy
Institute has identified a genetic mutation responsible for a rare form of inherited hives induced by vibratory urticaria.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!